Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma

Author(s): Maurizio Zangari, Federica Cavallo, Guido Tricot

Journal Name: Current Pharmaceutical Biotechnology

Volume 7 , Issue 6 , 2006

Become EABM
Become Reviewer


Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.

Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [449 - 453]
Pages: 5
DOI: 10.2174/138920106779116838
Price: $65

Article Metrics

PDF: 2